A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer (NCT02985957)
Patients eligible to participate in this study will receive Ipilimumab alone, Nivolumab and Ipilimumab, or Cabazitaxel and Prednisone.
This clinical trial is for patients who have metastatic castration resistant Prostate Cancer (mCPRC ) that has progressed while on Docetaxel. This trial is investigating the safety and effects (good or bad) of specific doses of Ipilimumab along with Nivolumab in patients with prostate cancer. Nivolumab and ipilimumab are investigational immunotherapies, which means that they are not currently approved to treat metastatic prostate cancer.
What is the purpose?
This clinical trial’s objective is to find out whether Nivolumab, when combined with Ipilimumab, is safe and can slow down or stop the growth of mCPRC in patients who have progressed following prior Docetaxel treatment. Participation in this clinical trial is determined using a full eligibility criteria. Some key eligibility criteria are provided below.
You may be able to participate if:
Organization: Bristol-Myers Squibb (BMS)
If you are interested in this trial, review the following:
PHEN Contact: 617-481-4020
Please Note: This information is provided for educational and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.